+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Antisense Oligonucleotide"

From
From
From
From
Biopharmaceuticals Contract Manufacturing Market - Product Thumbnail Image

Biopharmaceuticals Contract Manufacturing Market

  • Report
  • May 2024
  • 200 Pages
  • Global
From
Exosomes- Pipeline Insight, 2025 - Product Thumbnail Image

Exosomes- Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 280 Pages
  • Global
From
RNA Interference- Pipeline Insight, 2025 - Product Thumbnail Image

RNA Interference- Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 204 Pages
  • Global
From
From
From
From
Innovation Insights: RNA-targeting Small Molecules - Product Thumbnail Image

Innovation Insights: RNA-targeting Small Molecules

  • Report
  • January 2025
  • 48 Pages
  • Global
From
Innovation Insights: Anti-sense Oligonucleotides - Product Thumbnail Image

Innovation Insights: Anti-sense Oligonucleotides

  • Report
  • December 2024
  • 51 Pages
  • Global
From
From
Loading Indicator

The Antisense Oligonucleotide market is a segment of the biotechnology industry that focuses on the development of drugs that use short strands of nucleic acids to target and inhibit the expression of specific genes. These drugs are used to treat a variety of diseases, including cancer, cardiovascular disease, and neurological disorders. Antisense oligonucleotides are designed to bind to a specific mRNA sequence, blocking the translation of the gene into a protein. This technology has the potential to revolutionize the treatment of many diseases, as it can be used to target specific genes without affecting other parts of the body. The Antisense Oligonucleotide market is highly competitive, with many companies developing and marketing their own products. Some of the major players in the market include Alnylam Pharmaceuticals, Ionis Pharmaceuticals, and Arrowhead Pharmaceuticals. Other companies in the market include Regulus Therapeutics, Dicerna Pharmaceuticals, and Quark Pharmaceuticals. Show Less Read more